Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CONSENSUS PROPOSAL FOR 5HT(3) ANTAGONISTS IN THE PREVENTION OF ACUTE EMESIS RELATED TO HIGHLY EMETOGENIC CHEMOTHERAPY - DOSE, SCHEDULE, ANDROUTE OF ADMINISTRATION
Autore:
GANDARA DR; ROILA F; WARR D; EDELMAN MJ; PEREZ EA; GRALLA RJ;
Indirizzi:
UNIV CALIF DAVIS,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,4501 X ST SUITE 3017 SACRAMENTO CA 95817 UNIV CALIF DAVIS,CTR CANC SACRAMENTO CA 95817 MONTELUCE POLICLIN,DIV MED ONCOL I-06122 PERUGIA ITALY PRINCESS MARGARET HOSP,ONTARIO CANC INST TORONTO ON M5G 2M9 CANADA VA NO CALIF HLTH CARE SYST MARTINEZ CA 94553 MAYO CLIN JACKSONVILLE FL 32224 ALTON OCHSNER MED FDN & OCHSNER CLIN NEW ORLEANS LA 70121
Titolo Testata:
Supportive care in cancer
fascicolo: 3, volume: 6, anno: 1998,
pagine: 237 - 243
SICI:
0941-4355(1998)6:3<237:CPF5AI>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
CISPLATIN-INDUCED EMESIS; ONDANSETRON PLUS DEXAMETHASONE; DOUBLE-BLIND; INTRAVENOUS ONDANSETRON; SEROTONIN ANTAGONIST; INDUCED NAUSEA; ANTIEMETIC EFFICACY; BREAST-CANCER; ORAL ONDANSETRON; DOLASETRON MESYLATE;
Keywords:
CHEMOTHERAPY INDUCED EMESIS; SEROTONIN RECEPTORS; ONDANSETRON; GRANISETRON; DOLESETRON; TROPISETRON;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
64
Recensione:
Indirizzi per estratti:
Citazione:
D.R. Gandara et al., "CONSENSUS PROPOSAL FOR 5HT(3) ANTAGONISTS IN THE PREVENTION OF ACUTE EMESIS RELATED TO HIGHLY EMETOGENIC CHEMOTHERAPY - DOSE, SCHEDULE, ANDROUTE OF ADMINISTRATION", Supportive care in cancer, 6(3), 1998, pp. 237-243

Abstract

Selective antagonists to the Type 3 serotonin receptor (5HT(3)) in combination with corticosteroids are now considered the standard of carefor the prevention of emesis from moderately to highly emetogenic chemotherapy. Here we address issues of optimal dose, schedule and route of administration of four currently available selectable 5HT(3) antagonists. This paper utilizes an evidence based medicine approach to the literature regarding this class of drugs, emphasizing the results large, randomized, controlled trials to make formal recommendations concerning optimal use of this important new class of anti-emetic agents. Weconclude that for each drug there is a plateau in therapeutic efficacy at a definable dose level above which further dose escalation does not improve outcome. Furthermore, a single dose is as effective as multiple doses or continuous infusion, and finally, emerging data demonstrate that the oral route is equally efficacious as the intravenous route of administration, even with highly emetogenic chemotherapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 06:35:57